2020 / 04

DOI: 10.24075/brsmu.2020.052
Copyright: © 2020 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Thrombogenicity in patients with ischemic stroke and pre-existing polycythemia vera

Tanashyan MM1, Shabalina AA1, Roitman EV1, Vavilova TV2, Kuznetsova PI1
About authors

1 Research Center of Neurology, Moscow, Russia

2 Almazov National Medical Research Centre, Saint Petersburg, Russia

Correspondence should be addressed: Alla A. Shabalina
Volokolamskoe shosse, 80/1, Moscow, 125367; ur.ygoloruen@anilabahs

About paper

Compliance with ethical standards: the study was approved by the local Ethics Committee (Protocol № 1–4/18 dated February 7, 2018). Informed consent was obtained from all study participants.

Author contribution: Tanashyan MM — study concept and design; discussion and manuscript preparation; Shablina AA — literature analysis; data acquisition and statistical analysis; results discussion; Roitman EV, Vavilova TV — literature analysis; results discussion; Kuznetsova PI — patient histories; results discussion.

Received: 2020-08-11 Accepted: 2020-08-25 Published online: 2020-09-01
|
  2. Suslina ZA, Tanashjan MM, Ionova VG. Ishemicheskij insul't: krov', sosudistaja stenka, antitromboticheskaja terapija. M.: Medicinskaja kniga, 2005; 248 s. Russian.
  3. Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ. 2020; 368: l6983. Published 2020 Feb 13. DOI: 10.1136/ bmj.l6983.
  4. Tanashyan MM, Melikyan AL, Kuznetsova PI, Raskurazhev AA, Shabalina AA, Konovalov RN. Brain MRI-findings in Ph-negative myeloproliferative disorders. Terapevticheskii Arkhiv. 2019; 91 (7): 29–34. Russian.
  5. Asakura H. Thrombosis in myeloproliferative neoplasms. The Japanese Journal of Clinical Hematology. 2018; 59 (8): 1034–41. DOI: 10.11406/rinketsu.59.1034.
  6. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017; 92 (1): 94–108. DOI:10.1002/ajh.24607.
  7. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8 (2): 15. Published 2018 Feb 9. DOI: 10.1038/s41408- 018-0054-y.
  8. Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016; 9: 18. Available from: https://doi. org/10.1186/s13045-016-0242-9.
  9. Moulard O, Mehta J, Olivares R, Iqbal U, Mesa RA. Epidemiology of Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the European Union (EU). Blood. 2012; 120 (21): 1744. Available from: https://doi.org/10.1182/blood. V120.21.1744.1744.
  10. Volkova MA, redaktor. Klinicheskaja onkogematologija: rukovodstvo dlja vrachej. M.: Medicina, 2007; 1144 s. Russian.
  11. Kozlova NS, Baksheev MG, Davydkin IL. Osobennosti narushenij mikrocirkuljacii u bol'nyh istinnoj policitemiej v sochetanii s arterial'noj gipertenziej. Izvestija Samarskogo nauchnogo centra RAN. 2015; 17 (2): 319–22. Russian.
  12. Davydkin IL, Shhukin YuV, redaktory. Poliklinicheskaja terapija: uchebnik. M.: GJeOTAR-Media, 2013; 688 s. Russian.
  13. Rukavicyn OA, redaktor. Gematologija: nacional'noe rukovodstvo. M.: GJeOTAR-Media, 2015; 776 s. Russian.
  14. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost. 2003; 29 (5): 451–8.
  15. Fujioka S. Rheological study on vascular occlusion and cellular hyperviscosity syndrome in polycythemia vera. Nihon Ketsueki Gakkai Zasshi. 1989; 52 (4): 688–95.
  16. Pratesi A, Vella A, Pasini E, Salvi F, Mascalchi M. Parkinsonism in polycythaemia vera probably due to manganism. Mov Disord. 2008; 23 (16): 2420–1. DOI: 10.1002/mds.22319.
  17. Cerquozzi S, Barraco D, Lasho T, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017; 7 (12): 662. Published 2017 Dec 27. DOI: 10.1038/s41408-017-0035-6.
  18. Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. Thrombosis. 2011; 2011 (1): 1–9. DOI: 10.1155/2011/794240.
  19. Frederiksen H, Szépligeti S, Bak M, Waleed G, Hasselbalch HC, Christiansen CF. Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms — Impact Of Comorbidity. Clinical Epidemiology. 2019; 11: 955–67. Available from: https://doi. org/10.2147/CLEP.S216787, 2019.
  20. Tanashjan MM, Kuznecova PI, Suborceva IN, Shabalina AA, Lagoda OV, Melikjan AL. Hronicheskaja i ostraja cerebrovaskuljarnaja patologija pri ph-negativnyh mieloproliferativyh zabolevanijah. Gematologija i transfuziologija. 2016; 61 (3): 146–50. Russian.
  21. Marton I, Pósfai É, Csomor A, Vécsei L, Borbényi Z, Sas K. Cerebrovascular Complications and Polycythaemia Vera. Pathol Oncol Res. 2019; 25 (1): 439–42. DOI: 10.1007/s12253-017- 0329-9.
  22. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24 (1): 35–41. DOI: 10.1161/01. str.24.1.35.
  23. Momot AP. Problema trombofilii v klinicheskoj praktike. Rossijskij zhurnal detskoj gematologii i onkologii. 2015; 1: 37–48.